Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Livzon Pharmaceutical Group ( (HK:1513) ) has shared an update.
Livzon Pharmaceutical Group has updated details of its proposed final dividend for the financial year ended 31 December 2025, declaring a cash payout of RMB 14.3 per 10 shares subject to shareholder approval on 29 May 2026. The company clarified the ex-dividend date of 16 June 2026, the record date of 17 June 2026, and a payment date of 13 July 2026, while also outlining withholding tax rates for non-resident enterprise shareholders, providing investors with clearer visibility on timing and after-tax returns.
The dividend will be paid in Hong Kong dollars with the applicable exchange rate to be announced, and Tricor Investor Services Limited remains the share registrar handling entitlement registrations. By confirming the timetable and tax treatment, Livzon is reinforcing its capital return policy and offering more certainty to institutional and cross-border investors assessing yield and cash flow expectations from the stock.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a pharmaceutical company listed in Hong Kong, focusing on the development, manufacture and sale of pharmaceutical products. The group operates in the broader healthcare sector, serving markets in mainland China and overseas through equity-listed shares and engaging a mix of executive, non-executive and independent directors in its governance structure.
Average Trading Volume: 914,703
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.41B
See more insights into 1513 stock on TipRanks’ Stock Analysis page.